No Data
No Data
Voyager Therapeutics Announces New Data From Two Preclinical Programs
Voyager Presents Robust Preclinical Data From Tau Targeting Gene Therapy and Antibody Programs at AD/PD 2025
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teleflex (TFX) and Voyager Therapeutics (VYGR)
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT)
Citi Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $11
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $30